These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 34461854)

  • 1. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
    Bissonnette RP; Cesario RM; Goodenow B; Shojaei F; Gillings M
    BMC Cancer; 2021 Aug; 21(1):969. PubMed ID: 34461854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
    Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
    Wang HQ; Mulford IJ; Sharp F; Liang J; Kurtulus S; Trabucco G; Quinn DS; Longmire TA; Patel N; Patil R; Shirley MD; Chen Y; Wang H; Ruddy DA; Fabre C; Williams JA; Hammerman PS; Mataraza J; Platzer B; Halilovic E
    Cancer Res; 2021 Jun; 81(11):3079-3091. PubMed ID: 33504557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
    Hicks KC; Knudson KM; Lee KL; Hamilton DH; Hodge JW; Figg WD; Ordentlich P; Jones FR; Rabizadeh S; Soon-Shiong P; Schlom J; Gameiro SR
    Clin Cancer Res; 2020 Feb; 26(3):704-716. PubMed ID: 31645354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
    Briere D; Sudhakar N; Woods DM; Hallin J; Engstrom LD; Aranda R; Chiang H; Sodré AL; Olson P; Weber JS; Christensen JG
    Cancer Immunol Immunother; 2018 Mar; 67(3):381-392. PubMed ID: 29124315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
    Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
    J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer.
    Shi Y; Fu Y; Zhang X; Zhao G; Yao Y; Guo Y; Ma G; Bai S; Li H
    Cancer Immunol Immunother; 2021 Jan; 70(1):61-73. PubMed ID: 32632663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK Inhibition Remodels the Immune Landscape of Mutant
    Yang B; Li X; Fu Y; Guo E; Ye Y; Li F; Liu S; Xiao R; Liu C; Lu F; Huang J; Qin T; Han L; Peng G; Mills GB; Sun C; Chen G
    Cancer Res; 2021 May; 81(10):2714-2729. PubMed ID: 33589518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner.
    Muramatsu T; Noguchi T; Sugiyama D; Kanada Y; Fujimaki K; Ito S; Gotoh M; Nishikawa H
    Int Immunol; 2021 Jan; 33(1):39-48. PubMed ID: 32729901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
    Tentler JJ; Lang J; Capasso A; Kim DJ; Benaim E; Lee YB; Eisen A; Bagby SM; Hartman SJ; Yacob BW; Gittleman B; Pitts TM; Pelanda R; Eckhardt SG; Diamond JR
    BMC Cancer; 2020 Nov; 20(1):1063. PubMed ID: 33148223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.
    Chen JS; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Sci Rep; 2022 Jan; 12(1):1100. PubMed ID: 35058524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade.
    Tu K; Yu Y; Wang Y; Yang T; Hu Q; Qin X; Tu J; Yang C; Kong L; Zhang Z
    ACS Appl Mater Interfaces; 2021 Aug; 13(33):39003-39017. PubMed ID: 34433253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer.
    Wang P; Zhong W; Huang Q; Zhu Y; Chen L; Ye K
    ACS Biomater Sci Eng; 2024 May; 10(5):3136-3147. PubMed ID: 38663028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response.
    Sato Y; Fu Y; Liu H; Lee MY; Shaw MH
    BMC Cancer; 2021 Nov; 21(1):1222. PubMed ID: 34774008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodal Molecular Imaging Detects Early Responses to Immune Checkpoint Blockade.
    Saida Y; Brender JR; Yamamoto K; Mitchell JB; Krishna MC; Kishimoto S
    Cancer Res; 2021 Jul; 81(13):3693-3705. PubMed ID: 33837042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer.
    Shin HS; Choi J; Lee J; Lee SY
    Cancer Res Treat; 2022 Apr; 54(2):458-468. PubMed ID: 34517693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
    Que Y; Zhang XL; Liu ZX; Zhao JJ; Pan QZ; Wen XZ; Xiao W; Xu BS; Hong DC; Guo TH; Shen LJ; Fan WJ; Chen HY; Weng DS; Xu HR; Zhou PH; Zhang YZ; Niu XH; Zhang X
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
    Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor perfusion enhancement by ultrasound stimulated microbubbles potentiates PD-L1 blockade of MC38 colon cancer in mice.
    Li N; Tang J; Yang J; Zhu B; Wang X; Luo Y; Yang H; Jang F; Zou J; Liu Z; Wang Z
    Cancer Lett; 2021 Feb; 498():121-129. PubMed ID: 33129956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.
    Yu P; Steel JC; Zhang M; Morris JC; Waldmann TA
    Clin Cancer Res; 2010 Dec; 16(24):6019-28. PubMed ID: 20924130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.